Neurology

FDA-approved early Alzheimer medications should be covered by Medicare and other insurers and made immediately available to all those who will benefit.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Medicare’s restrictive coverage policies are denying patients with early Alzheimer's disease access to novel treatments. And private payers are following suit.

Help young patients with migraine (and their parents) get and stay prepared for the shift from home to college with this migraine survival kit checklist.

Your daily dose of the clinical news you may have missed.

Updated mRNA COVID-19 vaccines, the first orally disintegrating tablet approved for pregnancy prevention, and 5 more.

One in 9 primary care encounters involved a mental health condition, according to an analysis of over 350 million primary care visits.

Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.

Individuals with migraine who failed to respond to up to 4 previous migraine preventive treatments saw fewer monthly migraine and headache days after 1 infusion of Lu AG90222.

Based on its acceptance of the resubmission, FDA has assigned a PDUFA action goal date of January 31, 2025 for AXS-07.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

Your daily dose of the clinical news you may have missed.

Type 2 diabetes and prediabetes were associated with accelerated brain aging, particularly among men and persons with poor cardiometabolic health, according to new research.

The increase in the adult population with and at risk for dementia portends future burden among groups and communities with the fewest resources to cope.

Investigators found as much as a 2-fold difference in being diagnosed with dementia across the US, even after controlling for common individual risk factors.

Your daily dose of the clinical news you may have missed.

Findings from a new study suggest high-intensity interval training may be more effective in improving individuals’ cardiorespiratory fitness poststroke than moderate-intensity continuous training.

New study findings suggest that in older adults stable HbA1c within individualized target ranges over time may help reduce risk of Alzheimer disease and other dementias.

The lecanemab Clarity AD open label extension study returned no new safety signals and data reflect the therapy's disease modifying effects on key biomarkers.

A blood test had a diagnostic accuracy of 91% compared with 61% accuracy by primary care clinicians and 73% by dementia specialists, according to new research.

Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.

Your daily dose of the clinical news you may have missed.

Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.

Your daily dose of the clinical news you may have missed.

In contrast, men did not face the same increased risk of cerebrovascular disease later in life, reported authors of a new study.

The FDA has assigned a PDUFA action date of January 25, 2025 for the monthly IV maintenance dose.

The autoinjector delivers a weekly maintenance dose of 360 mg lecanemab for individuals who have completed biweekly treatment initiation by IV infusion.

From top barriers in seeking treatment to how well mental health issues are identified and treated, find out what US adults really think about the mental health care system.

The AdComm plans to review data from the TRAILBLAZER-ALZ 2 phase 3 clinical trial that served as the foundation for Eli Lilly's original BLA submission to the FDA.